Skip to main content Back to Top
Advertisement

5/11/2020

Bupivacaine with Epinephrine Injection

Products Affected - Description

    • Bupivacaine (with epinephrine 1:200,000) injection, Pfizer, 0.25%, 10 mL vial, 50 count, NDC 00409-9042-01
    • Bupivacaine (with epinephrine 1:200,000) injection, Pfizer, 0.25%, 30 mL vial, 100 count, NDC 00409-9042-17
    • Bupivacaine (with epinephrine 1:200,000) injection, Pfizer, 0.25%, 50 mL vial, 25 count, NDC 00409-9043-01
    • Bupivacaine (with epinephrine 1:200,000) injection, Pfizer, 0.5%, 10 mL vial, 50 count, NDC 00409-9045-01
    • Bupivacaine (with epinephrine 1:200,000) injection, Pfizer, 0.5%, 30 mL vial, 100 count, NDC 00409-9045-17
    • Bupivacaine (with epinephrine 1:200,000) injection, Pfizer, 0.5%, 50 mL vial, 25 count, NDC 00409-9046-01
    • Marcaine (with epinephrine 1:200,000) injection, Pfizer, 0.25%, 10 mL vial, 10 count, NDC 00409-1746-10
    • Marcaine (with epinephrine 1:200,000) injection, Pfizer, 0.25%, 30 mL vial, 10 count, NDC 00409-1746-30
    • Marcaine (with epinephrine 1:200,000) injection, Pfizer, 0.25%, 50 mL vial, 1 count, NDC 00409-1752-50
    • Marcaine (with epinephrine 1:200,000) injection, Pfizer, 0.5%, 10 mL vial, 10 count, NDC 00409-1749-10
    • Marcaine (with epinephrine 1:200,000) injection, Pfizer, 0.5%, 30 mL vial, 10 count, NDC 00409-1749-29
    • Marcaine (with epinephrine 1:200,000) injection, Pfizer, 0.5%, 50 mL vial, 1 count, NDC 00409-1755-50
    • Sensorcaine (with epinephrine 1:200,000) injection, Fresenius Kabi, 0.25%, 50 mL vial, 25 count, NDC 63323-0461-57
    • Sensorcaine (with epinephrine 1:200,000) injection, Fresenius Kabi, 0.5%, 50 mL vial, 25 count, NDC 63323-0463-57
    • Sensorcaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 0.25%, 10 mL vial, 25 count, NDC 63323-0468-17
    • Sensorcaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 0.25%, 30 mL vial, 25 count, NDC 63323-0468-37
    • Sensorcaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 0.5%, 10 mL vial, 25 count, NDC 63323-0462-17
    • Sensorcaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 0.5%, 30 mL sterile pack vial, 5 count, NDC 63323-0462-31
    • Sensorcaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 0.5%, 30 mL vial, 25 count, NDC 63323-0462-37

Reason for the Shortage

    • Fresenius Kabi has bupivacaine and epinephrine on shortage due to increased demand and manufacturing delays.
    • Pfizer has bupivacaine with epinephrine on shortage due to manufacturing delays.

Available Products

    • Sensorcaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 0.75%, 30 mL vial, 25 count, NDC 63323-0460-37

Estimated Resupply Dates

    • Fresenius Kabi has 0.25% Sensorcaine-MPF with epinephrine 10 mL vials on back order and the company estimates a release date of early- to mid-June 2020. The 0.25% Sensorcaine-MPF with epinephrine 30 mL vials are on back order and the company estimates a release date of mid-May 2020. The 0.25% Sensorcaine with epinephrine 50 mL vials are on back order and the company estimates a release date of mid-May 2020. The 0.5% Sensorcaine-MPF with epinephrine 10 mL vials are on back order and the company estimates a release date of early-June 2020. The 0.5% Sensorcaine-MPF with epinephrine 30 mL vials are on back order and the company estimates a release date of mid-May 2020. The 0.5% Sensorcaine with epinephrine 50 mL vials are on back order and the company estimates a release date of mid-May 2020. The 0.5% Sensorcaine-MPF with epinephrine 30 mL sterile packs are on back order and the company cannot estimate a release date.
    • Pfizer has 0.25% bupivacaine with epinephrine 10 mL preservative-free vials on back order and the company estimates a release date of June 2021. The 0.25% bupivacaine with epinephrine 30 mL preservative-free vials are on back order and the company estimates a release date of June 2021. The 0.25% bupivacaine with epinephrine 50 mL vials are on back order and the company estimates a release date of June 2021. The 0.5% bupivacaine with epinephrine 10 mL preservative-free vials are on back order and the company estimates a release date of June 2021. The 0.5% bupivacaine with epinephrine 30 mL preservative-free vials are on back order and the company estimates a release date of June 2021.The 0.5% bupivacaine with epinephrine 50 mL vials are on back order and the company estimates a release date of June 2021.
    • Pfizer has 0.25% Marcaine with epinephrine 10 mL preservative-free vials on back order and the company estimates a release date of June 2021. The 0.25% Marcaine with epinephrine 30 mL preservative-free vials are on back order and the company estimates a release date of June 2021. The 0.25% Marcaine with epinephrine 50 mL vials are on back order and the company estimates a release date of June 2021. The 0.5% Marcaine with epinephrine 10 mL preservative-free vials are on back order and the company estimates a release date of June 2021. The 0.5% Marcaine with epinephrine 30 mL preservative-free vials are on back order and the company estimates a release date of June 2021. The 0.5% Marcaine with epinephrine 50 mL vials are on back order and the company estimates a release date of June 2021.

Updated

Updated May 11, 2020 by Michelle Wheeler, PharmD, Drug Information Specialist. Created September 2, 2016 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.